《Medicalxpress,12月8日,Breakthrough COVID-19 saliva amplified antigen rapid test is as sensitive as PCR test》

  • 来源专题:COVID-19科研动态监测
  • 编译者: YUTING
  • 发布时间:2021-12-15
  • A potentially game-changing antigen rapid test (ART) technology to diagnose COVID-19 has been developed by scientists in Singapore. Using a proprietary on-kit amplification technique, a person's saliva can be self-administered or tested for the SARS-CoV-2 virus at the point-of-care with sensitivity higher than current ART tests and close to that of laboratory-based polymerase chain reaction (PCR) tests.

    Dubbed the Parallel Amplified Saliva rapid POint-of-caRe Test (PASPORT), the technology produces results in minutes, without the need for additional equipment or specially-trained personnel. The invention was borne out of a research collaboration between Duke-NUS Medical School, Singapore General Hospital (SGH) and National Cancer Centre Singapore (NCCS)—collectively member institutes of the SingHealth Duke-NUS Academic Medical Centre—and the National University of Singapore (NUS).

    With the impending availability of oral antiviral drugs against SARS-CoV-2, COVID-19 could potentially be diagnosed and treated in the primary care setting in the future. A test that can be done on-site will enable doctors to diagnose COVID-19 accurately and prescribe the drugs appropriately. Moreover, with its anticipated low cost and ease of use as compared to PCR tests, PASPORT could aid Singapore and countries around the world in making early diagnosis of COVID-19 to initiate appropriate case management. The research was published online on Monday, 6 December, 2021, in the journal Microchimica Acta as a feature article in their series, 'From Bench to Hand'.

    "Testing is an indispensable tool in the management of COVID-19 cases. Although PCR has been the gold standard, it requires trained personnel and laboratory infrastructure," said lead inventor Dr. Danny Jian Hang Tng, Medical Officer at the Department of Infectious Diseases, SGH, and an adjunct Research Fellow at Duke-NUS' Emerging Infectious Diseases (EID) Programme. Dr. Tng, who graduated from Duke-NUS in 2019, added, "A reliable and painless saliva antigen test that is affordable and convenient to perform would encourage more to be tested, and more frequent testing. This may enable us to manage COVID-19 more effectively not only at the point of care, but also in settings such as airports, conventions and even at home."

  • 原文来源:https://medicalxpress.com/news/2021-12-breakthrough-covid-saliva-amplified-antigen.html
相关报告
  • 《Medicalxpress,12月13日,Scientists develop an RNA-based breath test to detect COVID-19》

    • 来源专题:COVID-19科研动态监测
    • 编译者:YUTING
    • 发布时间:2021-12-18
    • In a new study in The Journal of Molecular Diagnostics, investigators report on the design and testing of a breathalyzer, known as the Bubbler, that relies on viral RNA detection to diagnose SARS-CoV-2. Its name is derived from the bubbling sound that occurs when the patient exhales into the device. The Bubbler not only reverse transcribes RNA from airborne virus particles into DNA to be tested via PCR but can also barcode that DNA, allowing samples to be linked directly to the patient they have come from and be used for sequencing. It can be used for simultaneous batches of pooled samples and provides additional information such as viral load and strain identity and eliminates the need for stabilizing a sample, potentially allowing the assay to be performed at home. "Involvement of the lower respiratory tract is often a precursor to severe COVID-19, so there is an argument for a more direct sampling focused on exhaled breath," explained lead investigator William G. Fairbrother, Ph.D., professor in the department of molecular biology, cell biology and biochemistry at Brown University in Providence, RI, U.S. Virus detection by the Bubbler is similar to a hospital-swab PCR test; however, it is a better measure of risk of contagion as it detects airborne viral particles. Swab tests can return a positive result for months after infection as they detect viral RNA fragments in cells that persist in previously infected cells. The Bubbler can also be adapted for environmental sampling in hospitals, transportation hubs, and closed environments like offices, ships, and planes, the investigators report. Seventy patients treated in the Emergency Department of Rhode Island Hospital between May 2020 and January 2021 were screened. The study tested samples from three points in the respiratory tract. Tongue scrapes from the mouth (saliva/tongue scrapes) and from 15 seconds of exhaled breath collected in the Bubbler were compared to those from a conventional nasopharyngeal swab PCR test. The Bubbler is a glass tube with a glass pipette through which patients can exhale. The tube is filled with a reverse transcription reaction mixture and cold mineral oil.
  • 《Nature,2月4日,Saliva is more sensitive than nasopharyngeal or nasal swabs for diagnosis of asymptomatic and mild COVID-19 infection》

    • 来源专题:COVID-19科研动态监测
    • 编译者:zhangmin
    • 发布时间:2021-02-25
    • Saliva is more sensitive than nasopharyngeal or nasal swabs for diagnosis of asymptomatic and mild COVID-19 infection Alvin Kuo Jing Teo, Yukti Choudhury, Iain Beehuat Tan, Chae Yin Cher, Shi Hao Chew, Zi Yi Wan, Lionel Tim Ee Cheng, Lynette Lin Ean Oon, Min Han Tan, Kian Sing Chan & Li Yang Hsu Scientific Reports volume 11, Article number: 3134 (2021) Abstract We aimed to test the sensitivity of naso-oropharyngeal saliva and self-administered nasal (SN) swab compared to nasopharyngeal (NP) swab for COVID-19 testing in a large cohort of migrant workers in Singapore. We also tested the utility of next-generation sequencing (NGS) for diagnosis of COVID-19. Saliva, NP and SN swabs were collected from subjects who presented with acute respiratory infection, their asymptomatic roommates, and prior confirmed cases who were undergoing isolation at a community care facility in June 2020. All samples were tested using RT-PCR. SARS-CoV-2 amplicon-based NGS with phylogenetic analysis was done for 30 samples. We recruited 200 subjects, of which 91 and 46 were tested twice and thrice respectively. In total, 62.0%, 44.5%, and 37.7% of saliva, NP and SN samples were positive. Cycle threshold (Ct) values were lower during the earlier period of infection across all sample types. The percentage of test-positive saliva was higher than NP and SN swabs. We found a strong correlation between viral genome coverage by NGS and Ct values for SARS-CoV-2. Phylogenetic analyses revealed Clade O and lineage B.6 known to be circulating in Singapore. We found saliva to be a sensitive and viable sample for COVID-19 diagnosis.